Last reviewed · How we verify
Paromomycin Alone topical cream
Paromomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and when applied topically as a cream, it kills or inhibits the growth of susceptible microorganisms on the skin surface.
Paromomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and when applied topically as a cream, it kills or inhibits the growth of susceptible microorganisms on the skin surface. Used for Cutaneous leishmaniasis (topical treatment).
At a glance
| Generic name | Paromomycin Alone topical cream |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Paromomycin works by disrupting bacterial protein synthesis through irreversible binding to the bacterial 30S ribosomal subunit, leading to misreading of mRNA codons and ultimately cell death. As a topical cream formulation, it achieves high local concentrations at the site of infection while minimizing systemic absorption. This mechanism makes it effective against a range of gram-negative and gram-positive bacteria, as well as certain parasites.
Approved indications
- Cutaneous leishmaniasis (topical treatment)
Common side effects
- Local skin irritation
- Erythema
- Pruritus
Key clinical trials
- Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis (PHASE2, PHASE3)
- Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (PHASE3)
- Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) (PHASE2)
- Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama (PHASE2)
- Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: